Herceptin, Trastuzumab Newswire (Page 6)

Herceptin, Trastuzumab Newswire (Page 6)

Comprehensive Real-Time News Feed for Herceptin, Trastuzumab (generic). (Page 6)

Results 101 - 120 of 844 in Herceptin, Trastuzumab (generic)

  1. Novel trial approaches may help to make cancer treatments more preciseRead the original story w/Photo

    May 23, 2016 | Medical News Today

    Newer trial designs may help to personalize cancer treatments based on DNA alterations in tumors, rather than on primary tumor site or stage of disease. The result could be more effective treatments.

    Comment?

  2. Little cost difference between tests to diagnose coronary heart diseaseRead the original story w/Photo

    May 22, 2016 | EurekAlert!

    For patients with suspected coronary artery disease , computed tomographic angiography and functional diagnostic testing strategies have similar costs through 3 years of follow up. Results of this prospective economic study are published in Annals of Internal Medicine .

    Comment?

  3. DECT trial shows combination of epirubicin and trastuzumab improves...Read the original story w/Photo

    May 23, 2016 | Medical News

    The study entitled "A phase II neoadjuvant sequential regimen of docetaxel followed by high-dose epirubicin in combination with cyclophosphamide administered concurrently with trastuzumab. The DECT trial" has recently appeared in the Journal of Cell Physiology , an international, per-reviewed journal focused on cancer-related issues.

    Comment?

  4. Concurrent Administration of Antrhacyclines and Trastuzumab in Breast ...Read the original story

    May 20, 2016 | Newswise

    Philadelphia-Rome, USA-ITALY May 2016. The study entitled "A phase II neoadjuvant sequential regimen of docetaxel followed by high-dose epirubicin in combination with cyclophosphamide administered concurrently with trastuzumab.

    Comment?

  5. Article ImageRead the original story w/Photo

    May 20, 2016 | Plymouth Evening Herald

    A cancer sufferer whose life was saved by an experimental drug has condemned health funding bosses for denying it to other patients. Jenny McCabe, from Camborne, took part in a trial of the drug Perjeta at the Royal Cornwall Hospital after she was diagnosed with an aggressive form of breast cancer.

    Comment?

  6. Breast cancer drug rejected for NHS despite doubling destruction of tumoursRead the original story w/Photo

    May 19, 2016 | Redditch Advertiser

    We want you to enjoy your visit to our website. That's why we use cookies to enhance your experience.

    Comment?

  7. Roche breast cancer drug Perjeta rejected by UK cost agencyRead the original story w/Photo

    May 19, 2016 | Channelnewsasia.com

    Roche's breast cancer drug Perjeta, or pertuzumab, has been turned down for use on Britain's state health service, making it the latest in a number of pricey new cancer treatments deemed not to offer value for money. Roche tablets are seen positioned in front of a displayed Roche logo in this January 22, 2016 file illustration photo.

    Comment?

  8. Merrimack To Present On Extensive Oncology Pipeline At The 2016 ASCO Annual MeetingRead the original story

    May 18, 2016 | BioSpace

    Final results from a Phase 1 study evaluating the safety, pharmacology and initial efficacy of MM-151 will be presented in a Poster Discussion Session. Merrimack will also present on the results from its Phase 3 NAPOLI-1 study of ONIVYDEA , as well as on multiple therapeutic candidates from its antibody engineering and antibody-directed nanotherapeutic technology platforms in six poster sessions.

    Comment?

  9. Pretreatment neutrophil-to-lymphocyte ratio is correlated with...Read the original story w/Photo

    May 19, 2016 | BioMed Central

    A high neutrophil-to-lymphocyte ratio may be related to increased mortality in patients with lung, colorectal, stomach, liver, and pancreatic cancer. To date, the utility of NLR to predict the response to neoadjuvant chemotherapy has not been studied.

    Comment?

  10. Merrimack to Present on Extensive Oncology Pipeline at the 2016 American Society of...Read the original story

    May 18, 2016 | Freshnews

    Merrimack Pharmaceuticals, Inc. today announced that it will present on its extensive oncology pipeline at the 2016 American Society of Clinical Oncology Annual Meeting, June 3-7, 2016 at McCormick Place, Chicago, Illinois. Final results from a Phase 1 study evaluating the safety, pharmacology and initial efficacy of MM-151 will be presented in a Poster Discussion Session.

    Comment?

  11. Entinostat Data to be Highlighted at the American Society of Clinical ...Read the original story

    May 18, 2016 | GlobeNewswire

    Syndax Pharmaceuticals, Inc. , a clinical stage biopharmaceutical company focused on developing entinostat in multiple cancer indications, today announced that clinical data from the National Cancer Institute's Cancer Therapy Evaluation Program will be presented at the 52nd Annual Meeting of the American Society of Clinical Oncology , which is being held from June 3 to June 7, 2016 in Chicago, Illinois. Preliminary results from ENCORE-601, a Phase 1b/2, open-label trial evaluating entinostat in combination with Keytruda A in non-small cell lung cancer and melanoma patients are available as a published abstract only at abstract.asco.org.

    Comment?

  12. Synthon Advances Clinical Evaluation Of Anti-HER2 ADC SYD985 In An...Read the original story

    May 17, 2016 | BioSpace

    Nijmegen, the Netherlands, 18 May 2016 ? Synthon Biopharmaceuticals today announced the initiation of the second part of its ongoing Phase I clinical trial with the investigational anti-HER2 antibody-drug conjugate SYD985. The second part will see 48 additional heavily pre-treated patients with HER2-positive breast cancer enrolled into the SYD985.001 trial.

    Comment?

  13. Synthon advances clinical evaluation of anti-HER2 ADC SYD985 in an expanded cohort of...Read the original story

    May 18, 2016 | Freshnews

    Synthon Biopharmaceuticals today announced the initiation of the second part of its ongoing Phase I clinical trial with the investigational anti-HER2 antibody-drug conjugate SYD985. The second part will see 48 additional heavily pre-treated patients with HER2-positive breast cancer enrolled into the SYD985.001 trial.

    Comment?

  14. Loss of ARID1A activates ANXA1, which serves as a predictive biomarker for trastuzumab resistance.Read the original story

    May 16, 2016 | CiteULike

    Despite the substantial progress in the development of targeted anti-cancer drugs, treatment failure due to primary or acquired resistance is still a major hurdle in the effective treatment of most advanced human cancers. Understanding these resistance mechanisms will be instrumental to improve personalized cancer treatment.

    Comment?

  15. Triple-negative breast cancer target is foundRead the original story w/Photo

    May 13, 2016 | PhysOrg Weblog

    UC Berkeley researchers have found a long-elusive Achilles' heel within "triple-negative" breast tumors, a common type of breast cancer that is difficult to treat. The scientists then used a drug-like molecule to successfully target this vulnerability, killing cancer cells in the lab and shrinking tumors in mice.

    Comment?

  16. Abstract P4-14-06: Neoadjuvant chemotherapy with docetaxel,...Read the original story

    May 12, 2016 | CiteULike

    Abstract P4-14-06: Neoadjuvant chemotherapy with docetaxel, carboplatin and weekly trastuzumab is active in HER2-positive early breast cancer: Results after a median follow-up of over 4 years Cancer Research , Vol. 76, No.

    Comment?

  17. Up to 55% price cut for cancer drugs, 53 othersRead the original story w/Photo

    May 11, 2016 | The Times of India

    Prices of these medicines have been fixed on priority because these are commonly used and are new to the list. Prices of these medicines have been fixed on priority because these are commonly used and are new to the list.

    Comment?

  18. .com | Unaffordable healthcare is fatal for the poor - MotsoalediRead the original story w/Photo

    May 10, 2016 | News24

    Ranting on social media about your frustrations is wrong, but people should try and understand where this white frustration is coming from, writes Robin Mun-Gavin . Cape Town If no drastic action is taken against unaffordable cancer and TB drugs, the country will be counting body bags like it was at war, Health Minister Aaron Motsoaledi said on Tuesday.

    Comment?

  19. Biosimilars in India News: Recent Guidelines from India's CDSCO ...Read the original story w/Photo

    May 9, 2016 | JD Supra

    A recent court ruling and a new publication on guidelines for biosimilars in India may offer further guidance on what biosimilar and biologic stakeholders can expect from Indian regulatory authorities. In late March, India's Central Drugs Standard Control Organization published Proposed Revised Guidelines on Similar Biologics , offering guidance on the regulatory requirements for biosimilars in India.

    Comment?

  20. Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in...Read the original story

    May 5, 2016 | CiteULike

    Trastuzumab emtansine versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA. We characterized the incidence of central nervous system metastases after treatment with trastuzumab emtansine versus capecitabine-lapatinib , and treatment efficacy among patients with pre-existing CNS metastases in the phase III EMILIA study.

    Comment?